Related Experiment Video
Updated: Nov 28, 2025

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
Published on: April 25, 2025
A SORAFENIB INDUCED MODEL OF GLOMERULAR KIDNEY DISEASE
A Stavniichuk1, O Savchuk1, Abdul Hye Khan2
1Taras Shevchenko National University, Kyiv, Ukraine.
Abstract:
Glomerular injury and proteinuria are important pathophysiological features of chronic kidney disease. In the present study, we provide data on a glomerular injury model that was developed using the cancer chemotherapy drug sorafenib. Sorafenib is a tyrosine kinase inhibitor that acts via the vascular endothelial growth factor (VEGF) signaling pathway and is widely used to treat a variety of cancers. On the other hand, sorafenib causes serious renal side effects in patients including the development of chronic kidney disease. The current study aimed to utilize the nephrotoxic property of sorafenib to develop a rat model for chronic kidney disease. We demonstrate that rats administered sorafenib for 8 weeks along with a high salt diet (8% NaCl enriched) develop hypertension (80mmHg higher systolic blood pressure), proteinuria (75% higher), and 4-fold higher glomerular injury compared to vehicle-treated normal control rat. Sorafenib induced glomerular injury was associated with decreased (20-80% lower) renal mRNA expression of key glomerular structural proteins such as nephrin, podocin, synaptopodin, and podoplanin compared to vehicle-treated normal control rat. Renal cortical endothelial-to-mesenchymal transition (EndoMT) was activated in the sorafenib induced glomerular injury model. In the sorafenib treated rats, the renal EndoMT was evident with 20% lower mRNA expression of an endothelial marker WT-1 and 2 to 3-fold higher expression of mesenchymal markers Col III, FSP-1, α-SMA, and vimentin. In conclusion, we developed a rat pre-clinical chronic kidney disease model that manifest glomerular injury. We further demonstrate that the glomerular injury in this model is associated with decreased renal mRNA expression of key glomerular structural proteins and an activated kidney EndoMT.
Insights
Researchers developed a rat model for chronic kidney disease using sorafenib, a cancer drug. This model shows key features of kidney disease, including glomerular injury and protein loss, aiding future research.
Area of Science:
- Nephrology
- Pharmacology
- Oncology
Background:
- Glomerular injury and proteinuria are hallmarks of chronic kidney disease (CKD).
- Sorafenib, a tyrosine kinase inhibitor targeting VEGF signaling, is used in cancer therapy but causes renal side effects.
- Developing reliable preclinical models for CKD is crucial for understanding disease mechanisms and testing interventions.
Purpose of the Study:
- To establish a novel rat model of chronic kidney disease (CKD) utilizing the nephrotoxic effects of sorafenib.
- To characterize the pathological and molecular changes in the kidney following sorafenib administration.
Main Methods:
- Rats were administered sorafenib and a high-salt diet (8% NaCl) for 8 weeks.
- Physiological parameters (blood pressure, proteinuria) and glomerular injury were assessed.
- Renal mRNA expression of structural proteins (nephrin, podocin, etc.) and markers of endothelial-to-mesenchymal transition (EndoMT) were quantified.
Main Results:
- Sorafenib-treated rats developed significant hypertension, proteinuria, and glomerular injury compared to controls.
- A marked decrease in mRNA expression of key glomerular structural proteins was observed.
- Evidence of activated renal cortical endothelial-to-mesenchymal transition (EndoMT) was detected, indicated by altered expression of endothelial and mesenchymal markers.
Conclusions:
- A reproducible rat model of sorafenib-induced chronic kidney disease (CKD) characterized by glomerular injury has been successfully developed.
- The model demonstrates molecular alterations including reduced expression of essential glomerular proteins and activation of kidney EndoMT.
- This preclinical model offers a valuable tool for investigating CKD pathogenesis and evaluating potential therapeutic strategies.
Related Concept Videos
Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
Nephrotic Syndrome I : Introduction
Acute Kidney Injury II: Pathophysiology
Nephrons
Renal Drug Excretion: Glomerular Filtration
Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent arterioles....
Chronic Kidney Disease II: Clinical Manifestations

